Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.

Item

http://www.wikidata.org/entity/Q34439666

Q34439666

about

Lack of methemoglobinemia with flutamide.Bicalutamide dosages used in the treatment of prostate cancer.Androgen deprivation therapy for prostate cancer-review of indications in 2010 An evaluation of bicalutamide in the treatment of prostate cancer.Bicalutamide (Casodex) in the treatment of prostate cancer.Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development.Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma.Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review Combination hormonal therapy: a reassessment within advanced prostate cancer.Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy.An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases.Side-effects of treatments for locally advanced prostate cancer.Rising prostate-specific antigen after primary prostate cancer therapy.Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target Evidence-based medicine: comparative analysis of luteinizing hormone-releasing hormone analogues in combination with external beam radiation and surgery in the treatment of carcinoma of the prostate.Managing the challenge of chemically reactive metabolites in drug development.Molecular targets for radiation oncology in prostate cancer.Switching and withdrawing hormonal agents for castration-resistant prostate cancer.Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.Controversies in the management of advanced prostate cancer.Palladium-catalyzed three-component diaryl sulfone synthesis exploiting the sulfur dioxide surrogate DABSO.An update on bicalutamide in the treatment of prostate cancer.Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.Androgen Deprivation for Prostatic Carcinoma: A Rationale for Choosing Components Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials

P2860

Q31989506-05541F0C-29FA-494F-88EB-0F23844514AE Q33604137-B764AA68-1DDD-461C-8611-62708C6F4110 Q34111603-E1F01D8A-A0E5-47AB-8E83-A9C9CE69EA88 Q34145167-1CBF8E76-B7B8-47D7-84D5-1192084B01D1 Q34293191-1AE57E49-CC67-4A2E-8AB8-56616D8AD8AC Q34394508-B1B39777-D12F-4718-863F-E403E766D668 Q34452166-796AA39A-E15D-4DA1-847D-9815A833494A Q34596863-BF8101CB-CBFA-4DE4-9172-740E8C5690DA Q34747437-BAEAA571-0D0E-4D3F-B950-A9FE4C0B66A3 Q35840364-8ADC5995-3C4B-4EAC-8003-FFD50532B752 Q35886568-EB8A3365-E8EB-4AF4-9906-FFFF54D00464 Q36023678-BA7FEB59-166E-4EE1-A877-BA87DE0BB855 Q36082100-87AA38C7-989F-4D3B-856B-B21C568EAFD3 Q36335068-DEBED4BA-A13D-4F5F-AA0C-6A7E26CCD22A Q36395149-4B204F30-C8E4-487D-AE67-3703728B6781 Q37606741-E0A8CE63-455C-470A-B41C-0E046CA8DFD5 Q37809569-778B6C8D-B31F-43B6-8E82-4439C658347C Q37860142-8B7FF4C2-06A8-4D29-A353-C466B12D048B Q38014447-7E5F3B2A-5973-4723-8DEF-C3D34733E556 Q38309205-D58E2221-FBBB-4D29-8C37-0D13BD094C91 Q38803264-B230894D-A0D8-4B30-A376-F91718064BB9 Q39776862-8535DF46-0465-49F2-9A94-2AE0F9879DDB Q42135671-0975927A-22EB-429B-BFCE-2EAECAC65FEE Q42821215-15714EE1-A106-4AB2-9D73-621FE99C3085 Q44911730-B0FB704E-EFE8-4839-8C8C-1DED721E8684 Q46694974-4A9CD9C9-7735-46A1-A357-3F3A90CF3970 Q46708843-DE55E829-797B-4871-8666-B78B74C07EF0 Q56672866-EA386E7D-5B75-4A0E-8554-E9353774DBE3 Q58761734-6EF1A847-2573-4336-8230-A3D11CE2CC00

P2860

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.

Item

http://www.wikidata.org/entity/Q34439666

description

1997 nî lūn-bûn

@nan

1997 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu